Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib in Resected NSCLC
NCT00621049Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2007
- Primary completion
- Jul 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Disease-free Survival at 1 year. Started Dec 2007; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00621049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621049.